|
US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
|
US4452773A
(en)
|
1982-04-05 |
1984-06-05 |
Canadian Patents And Development Limited |
Magnetic iron-dextran microspheres
|
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
|
US5019369A
(en)
|
1984-10-22 |
1991-05-28 |
Vestar, Inc. |
Method of targeting tumors in humans
|
|
US4690915A
(en)
|
1985-08-08 |
1987-09-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adoptive immunotherapy as a treatment modality in humans
|
|
US4795698A
(en)
|
1985-10-04 |
1989-01-03 |
Immunicon Corporation |
Magnetic-polymer particles
|
|
IN165717B
(enExample)
|
1986-08-07 |
1989-12-23 |
Battelle Memorial Institute |
|
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5219740A
(en)
|
1987-02-13 |
1993-06-15 |
Fred Hutchinson Cancer Research Center |
Retroviral gene transfer into diploid fibroblasts for gene therapy
|
|
ATE114507T1
(de)
|
1988-12-28 |
1994-12-15 |
Stefan Miltenyi |
Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien.
|
|
US5283173A
(en)
|
1990-01-24 |
1994-02-01 |
The Research Foundation Of State University Of New York |
System to detect protein-protein interactions
|
|
US5200084A
(en)
|
1990-09-26 |
1993-04-06 |
Immunicon Corporation |
Apparatus and methods for magnetic separation
|
|
US5827642A
(en)
|
1994-08-31 |
1998-10-27 |
Fred Hutchinson Cancer Research Center |
Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
|
|
DE19608753C1
(de)
|
1996-03-06 |
1997-06-26 |
Medigene Gmbh |
Transduktionssystem und seine Verwendung
|
|
US7939059B2
(en)
|
2001-12-10 |
2011-05-10 |
California Institute Of Technology |
Method for the generation of antigen-specific lymphocytes
|
|
US20030170238A1
(en)
|
2002-03-07 |
2003-09-11 |
Gruenberg Micheal L. |
Re-activated T-cells for adoptive immunotherapy
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
EP2520643B8
(en)
|
2007-12-07 |
2019-11-27 |
Miltenyi Biotec B.V. & Co. KG |
Sample processing systems and methods
|
|
US20120164718A1
(en)
|
2008-05-06 |
2012-06-28 |
Innovative Micro Technology |
Removable/disposable apparatus for MEMS particle sorting device
|
|
CA2735456C
(en)
|
2008-08-26 |
2021-11-16 |
City Of Hope |
Method and compositions for enhanced anti-tumor effector functioning of t cells
|
|
CN102421801B
(zh)
|
2009-03-10 |
2016-03-16 |
比奥根Ma公司 |
抗-bcma抗体
|
|
JP5956342B2
(ja)
|
2009-11-03 |
2016-07-27 |
シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ |
形質導入Ｔ細胞選択のためのトランケート上皮増殖因子レセプタ（ＥＧＦＲｔ）
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
AU2013246443B2
(en)
|
2012-04-11 |
2017-04-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors targeting B-cell maturation antigen
|
|
LT2884999T
(lt)
|
2012-08-20 |
2021-04-12 |
Fred Hutchinson Cancer Research Center |
Ląstelinės imunoterapijos būdas ir kompozicijos
|
|
RU2729401C2
(ru)
|
2012-10-02 |
2020-08-06 |
Мемориал Слоан-Кеттеринг Кэнсер Сентер |
Композиции и способы для иммунотерапии
|
|
JP5372297B1
(ja)
|
2012-12-20 |
2013-12-18 |
三菱電機株式会社 |
車載装置及びプログラム
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
US9108442B2
(en)
|
2013-08-20 |
2015-08-18 |
Ricoh Company, Ltd. |
Image forming apparatus
|
|
EP3131927B8
(en)
|
2014-04-14 |
2020-12-23 |
Cellectis |
Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
|
|
AU2015292744C1
(en)
|
2014-07-21 |
2021-01-21 |
Novartis Ag |
Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
|
|
EP3172231B1
(en)
|
2014-07-24 |
2021-05-05 |
Bluebird Bio, Inc. |
Bcma chimeric antigen receptors
|
|
BR112017005766B1
(pt)
|
2014-09-22 |
2022-10-25 |
Sacmi Cooperativa Meccanici Imola Societa' Cooperativa |
Linha de produção para a fabricação de produtos, de forma sucessiva e método para a produção de produtos individuais, de forma sucessiva, em ciclo contínuo, em uma linha de produção
|
|
CN113698497A
(zh)
|
2014-12-05 |
2021-11-26 |
纪念斯隆-凯特琳癌症中心 |
靶向b-细胞成熟抗原的嵌合抗原受体及其用途
|
|
HRP20210582T1
(hr)
|
2014-12-05 |
2021-09-03 |
Memorial Sloan Kettering Cancer Center |
Antitijela koja ciljaju antigen sazrijevanja b-stanice i postupci uporabe
|
|
US10383929B2
(en)
|
2014-12-12 |
2019-08-20 |
Bluebird Bio, Inc. |
BCMA chimeric antigen receptors
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
KR102427334B1
(ko)
|
2016-04-01 |
2022-08-03 |
카이트 파마 인코포레이티드 |
키메라 항원 및 t 세포 수용체 및 사용 방법
|
|
PL3896091T3
(pl)
|
2016-08-10 |
2024-04-29 |
Legend Biotech Ireland Limited |
Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania
|
|
MX2019005277A
(es)
|
2016-11-04 |
2019-09-27 |
Bluebird Bio Inc |
Composiciones de celulas t con car anti-bcma.
|
|
US20190030073A1
(en)
|
2016-12-02 |
2019-01-31 |
Cartesian Therapeutics, Inc. |
Cancer immunotherapy with highly enriched cd8+ chimeric antigen receptor t cells
|
|
EP3572427B1
(en)
|
2017-01-23 |
2025-06-25 |
CRAGE medical Co., Limited |
Bcma-targeting antibody and use thereof
|
|
US11066475B2
(en)
|
2017-11-01 |
2021-07-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
|
|
AU2019214183B2
(en)
|
2018-02-01 |
2022-04-07 |
Innovent Biologics (Suzhou) Co., Ltd. |
Fully human anti-B cell maturation antigen (BCMA) single chain variable fragment, and application thereof
|
|
BR112020018049A2
(pt)
|
2018-03-07 |
2020-12-29 |
Poseida Therapeutics, Inc. |
Composições de cartirina e métodos para uso
|
|
IL278854B2
(en)
*
|
2018-05-23 |
2026-01-01 |
Celgene Corp |
Multiple myeloma treatment and biomarker use for 4-(4-(4-(((2-(6,2-dioxopyridin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl-3-fluorobenzonitrile
|
|
US20210330788A1
(en)
*
|
2018-07-11 |
2021-10-28 |
Celgene Corporation |
Uses of anti-bcma chimeric antigen receptors
|
|
CA3111384A1
(en)
|
2018-09-05 |
2020-03-12 |
Poseida Therapeutics, Inc. |
Allogeneic cell compositions and methods of use
|
|
PE20211915A1
(es)
|
2018-12-01 |
2021-09-28 |
Allogene Therapeutics Inc |
Receptores de antigenos quimericos dirigidos al antigeno de maduracion de celulas b y sus metodos de uso
|
|
BR112022008522A2
(pt)
|
2019-11-05 |
2022-07-26 |
Celgene Corp |
Usos de receptores de antígeno quimérico anti-bcma
|
|
PE20221757A1
(es)
|
2020-02-24 |
2022-11-11 |
Allogene Therapeutics Inc |
Celulas t con car de bcma con actividades mejoradas
|